CV Sciences, Inc. (CVSI): Gross Profit
$6.75M
Year ended 2025-12-31
$6.26M
Trailing 12 months to 2026-06-30
+6.8%
3-year compound annual growth
-9.3%
5-year compound annual growth
0.0%
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.75M | -5.8% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $7.17M | +1.2% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $7.08M | +27.7% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $5.55M | -35.6% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $8.62M | -21.7% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $11.01M | -68.6% | 2022-04-04, From 2020-01-01 |
| 2019-12-31 | $35.09M | +3.6% | 2021-03-19, From 2019-01-01 |
| 2018-12-31 | $33.88M | +133.8% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $14.49M | +107.1% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $7.00M | +4.0% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $6.73M | n/c | 2017-03-31, From 2015-01-01 |
| 2014-12-31 | $5.80M | +355.7% | 2016-04-14, From 2014-01-01 |
| 2013-12-31 | $1.27M | n/a | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $0 | n/a | 2014-03-28, From 2012-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $6.75M | -5.8% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $11.47M | n/a |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.47M | +177.7% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $11.60M | -25.0% |
| uniQure N.V. (QURE) | 2025-12-31 | $14.41M | n/a |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $7.74M | -20.5% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $15.57M | +0.2% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $10.08M | -9.6% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $5.07M | -4.8% |
Compare CVSI, PYXS, TNXP, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗